Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
AnavexJohnson & Johnson
Last price
$1.25$253.79
Currency
USD
USD
$121M$616B
-38.81
-$0.14$6.58
1.140.21
0$5.28
02.10%
Sector
HealthHealth
Employees
34138,200
Ticker
$AVXL$JNJ
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $AVXL or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.